Cagrilintide
vs Semaglutide.
Compare cagrilintide and semaglutide by mechanism, REDEFINE 1 results, Phase 3 status, approval, side effects, and the limits of the randomized evidence.
What is the difference?
Cagrilintide and semaglutide are different peptide medicines and are not interchangeable. Cagrilintide is an investigational long-acting amylin analogue in the standalone RENEW Phase 3 program. Semaglutide is a GLP-1 receptor agonist with product-specific approvals, including WEGOVY for chronic weight management in defined populations. REDEFINE 1 randomized separate cagrilintide and semaglutide arms under one protocol and reported higher descriptive mean weight loss with semaglutide, but the cited sources do not establish a prespecified, statistically powered superiority test between those two monotherapy arms. Cagrilintide is not FDA approved and has no approved retail product or commercial price.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Cagrilintide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 52 matched NCT records
- Sponsor
- Novo Nordisk
Semaglutide
FDA-approved prescription drug
- Route
- Subcutaneous and oral
- Registry
- Dedicated medicine evidence record
- Sponsor
- Novo Nordisk Inc.
Cagrilintide vs Semaglutide: how direct is the evidence?
Cagrilintide and Semaglutide appeared in separate randomized arms of REDEFINE 1. The common protocol aligns important design fields, but the cited record does not necessarily establish that this exact pair was a prespecified and statistically powered superiority comparison.
Cagrilintide
Long-acting amylin analogue
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 monotherapy program
- Status
- Investigational - not FDA approved
Same trial, but the exact contrast may be descriptive.
Use the shared protocol as stronger descriptive context while checking whether the exact pairwise contrast was prespecified and powered.
REDEFINE 1Semaglutide
GLP-1 receptor agonist
- Route
- Subcutaneous and oral
- Stage
- NDA 215256 approved product record
- Status
- FDA-approved prescription drug
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 10
- Results posted
- 2
- Recruiting site observations
- 170
Outside this 13-program snapshot
This comparison uses an approved-medicine record here. A blank is a scope boundary, not evidence that no clinical trial or trial history exists.
Open the bounded clinical trial finder →Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Use the shared protocol as stronger descriptive context while checking whether the exact pairwise contrast was prespecified and powered.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Cagrilintide
Long-acting amylin analogue
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 monotherapy program
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT03856047 · NCT05567796 · NCT07220642 · NCT07220759
Semaglutide
GLP-1 receptor agonist
- Route
- Subcutaneous and oral
- Stage
- NDA 215256 approved product record
- Status
- FDA-approved prescription drug
- Featured trial anchors
- NDA 215256
Compare the field, then read the limit.
This comparison has stronger context than the usual cross-trial matchup because REDEFINE 1 included cagrilintide, semaglutide, CagriSema, and placebo in one randomized 68-week protocol. That common design helps align population, duration, lifestyle intervention, and analysis definitions. It still does not turn an exploratory reading of two arms into a regulatory claim that one monotherapy is superior, safer, or better for an individual. Semaglutide also spans multiple approved brands and labels, so every access or price statement must resolve to an exact product and country.
| Field | Cagrilintide | Semaglutide | How to interpret it |
|---|---|---|---|
| Mechanism | Long-acting amylin analogue | GLP-1 receptor agonist | The drugs act through different primary pathways, and receptor class alone cannot establish comparative benefit or safety. |
| REDEFINE 1 trial-product estimate | 11.8% mean weight loss at 68 weeks | 16.1% mean weight loss at 68 weeks | The figures share a randomized protocol, but descriptive separation is not automatically a powered superiority result. |
| REDEFINE 1 treatment-policy estimate | 11.5% mean weight loss at 68 weeks | 14.9% mean weight loss at 68 weeks | This estimand reflects outcomes regardless of adherence, while still requiring the same caution about the comparison objective. |
| Current status | Investigational monotherapy in RENEW Phase 3 | Ingredient in product-specific approved medicines, including WEGOVY | An active development program and an approved product record create different prescribing, access, price, and safety contexts. |
| Product identity | No FDA-approved cagrilintide product or price | Exact brand, application, presentation, indication, and country must be specified | Neither ingredient name authenticates a compounded preparation, research vial, imported product, or online seller claim. |
Why the headline numbers do not name a winner.
Under the REDEFINE 1 trial-product estimand, mean weight change at week 68 was 11.8% with cagrilintide and 16.1% with semaglutide, compared with 2.3% for placebo. Under the treatment-policy estimand, the reported values were 11.5%, 14.9%, and 3.0%, respectively. These same-protocol values provide descriptive randomized context, but the publications cited here do not establish that cagrilintide versus semaglutide was a prespecified and powered superiority comparison. The trial also studied exact investigational regimens, not every compounded, imported, or seller-labelled product using either ingredient name.
Keep the comparison honest.
- 01
Use REDEFINE 1 as same-protocol descriptive context, while checking whether the exact cagrilintide versus semaglutide contrast was prespecified and statistically powered.
- 02
Keep standalone cagrilintide separate from CagriSema, which combines cagrilintide with semaglutide and produced a different result in another randomized arm.
- 03
Resolve semaglutide to an exact approved product, label, presentation, indication, and jurisdiction before making access, price, safety, or availability claims.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →